A broader molecular map of breast cancer
Researchers at Vanderbilt-Ingram Cancer Center have assembled a large transcriptomic atlas of breast cancer, integrating data from more than 7,600 tumors across 22 independent studies. Published Nov. 3 in Cell Reports Medicine, the work is intended to provide a more detailed view of breast cancer biology than classifications based solely on standard pathology and receptor status.
A tumor transcriptome is the complete collection of RNA molecules produced by the tumor. Because RNA reflects which genes are active, transcriptomic analysis can reveal molecular features that are not necessarily apparent from conventional examination of tumor tissue.
The researchers describe the resulting atlas as an archipelago: distinct tumor populations form molecular “islands” that share biological features, treatment responses and clinical outcomes. The map identifies previously hidden forms of breast cancer that differ in prognosis, biology and treatment sensitivity, according to corresponding author Brian Lehmann.
Why existing categories can fall short
Breast cancer is commonly categorized using the presence or absence of estrogen, progesterone and HER2 receptors. Those markers remain central to treatment decisions. Transcriptomic profiling has already added molecular subtypes to that framework, but patients whose tumors receive the same broad label can still have very different clinical responses.
The new analysis addresses that variation by combining data at a substantially larger scale. Rather than treating traditional categories as the final description of a tumor, the atlas aims to locate tumors according to their full patterns of gene expression and associated clinical characteristics.
That distinction matters because a molecular classification is useful only if it can connect biological variation to practical consequences. The authors report that the tumor populations revealed in the atlas are associated with differing clinical outcomes, biological characteristics and therapeutic vulnerabilities.
A foundation for precision oncology
The study is not itself a new treatment guideline, but it establishes a research foundation for selecting therapies according to a tumor’s molecular characteristics rather than standard pathology alone. In principle, a more granular map could help researchers identify which tumors are most likely to respond to particular approaches and where existing classifications leave important differences unexplained.
The work also builds on prior research by Lehmann and Vanderbilt-Ingram Cancer Center colleague Jennifer Pietenpol, whose earlier studies helped define molecular subtypes of triple-negative breast cancer. Those studies showed that different triple-negative subtypes can have distinct treatment sensitivities.
For patients and clinicians, the promise is more individualized cancer care. The immediate implication, however, is scientific: the atlas supplies a shared dataset and framework for testing whether specific molecular tumor populations consistently predict outcomes or therapeutic response.
What comes next
Large cross-study analyses can uncover patterns that are difficult to see in individual datasets, particularly in a disease as heterogeneous as breast cancer. The next challenge is translating those patterns into validated tests and treatment strategies that work in clinical settings.
Still, the scale of the map makes it a potentially valuable reference for future breast cancer research. By charting molecular diversity across thousands of tumors, the researchers have created a clearer starting point for investigating why tumors that look similar by conventional measures can behave differently—and how treatment can be better matched to those differences.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
